JSKN016 not checked
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Injection; 100 mg (4.0 mL)/vial. Dosage: 6 mg/kg administered via intravenous infusion on Day 1 of each 21-day cycle”In the company’s words, NCT07533123 on ClinicalTrials.gov
- Tested for
- Advanced Non-small Cell Lung Cancer (2 trials), Triple Negative Breast Cancer, Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC), Advanced Malignant Solid Tumor
- Main trialPhase 3
- “Primary Endpoint of this Study: To compare Progression-Free Survival (PFS) (as assessed by a Blinded Independent Review Committee \[BIRC\] based on Response Evaluation Criteria in Solid Tumors \[RECIST v1.1\]) between JSKN016 and Treatment of Physician's Choice (TPC) in participants with unresectable locally advanced, recurrent, or metastatic triple-negative breast cancer (TNBC). To compare Overall Survival (OS) between JSKN016 and TPC in the treatment of unresectable locally advanced, recurrent, or metastatic TNBC.”In the company’s words, NCT07533123 on ClinicalTrials.gov
Other drugs for Advanced Non-small Cell Lung Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- CobimetinibRoche · Phase 2/3
- DivarasibRoche · Phase 3
- EntrectinibRoche · Phase 3
Coming up5
- 30 Jun 2027Phase 2 trial completes · ClinicalTrials.gov
- 30 Jun 2027Phase 1/2 trial completes · ClinicalTrials.gov
- Dec 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 30 Jun 2028Phase 1 trial completes · ClinicalTrials.gov
- 17 Mar 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 17 Mar 2029 | A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care | |
| Phase 2Not yet recruiting | 30 Jun 2027 | Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance: a Phase II Clinical Study | |
| Phase 1/2Recruiting | 30 Jun 2027 | Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer | |
| Phase 1/2Not yet recruiting | Dec 2027 | JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer | |
| Phase 1Recruiting | 17 May 2026 | To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors | |
| Phase 1Recruiting | 30 Jun 2028 | Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026